skinny.

Latest / The Top Line

The promise of molecular gates and what comes next

Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they can do harm.

The approach could be particularly promising for diseases of the brain, where traditional biologics face significant delivery challenges. Gate's first publicly disclosed program targets prion disease, but the company sees opportunities across inflammation, fibrosis and other…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.